• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Francisella Tularensis Infections - Pipeline Review, H2 2012 Product Image

Francisella Tularensis Infections - Pipeline Review, H2 2012

  • Published: November 2012
  • 40 pages
  • Global Markets Direct

Francisella Tularensis Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Francisella Tularensis Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Francisella Tularensis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections. Francisella Tularensis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Francisella Tularensis Infections.
- A review READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Francisella Tularensis Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Francisella Tularensis Infections 7
Francisella Tularensis Infections Therapeutics under Development by Companies 9
Pre-Clinical Stage Products 10
Comparative Analysis 10
Francisella Tularensis Infections Therapeutics – Products under Development by Companies 11
Companies Involved in Francisella Tularensis Infections Therapeutics Development 12
AlphaRx, Inc. 12
Aduro BioTech 13
Affinium Pharmaceuticals, Inc. 14
Achaogen Inc. 15
Evolva SA 16
EpiVax, Inc. 17
Tetraphase Pharmaceuticals Inc. 18
Francisella Tularensis Infections – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
ciprofloxacin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
EV-009 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Fabl Inhibitor Program - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
TP-271 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Lm Tularemia - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
EV-035 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
doxycycline - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ACHN-978 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Francisella Tularensis Infections Therapeutics – Drug Profile Updates 32
Francisella Tularensis Infections Therapeutics – Discontinued Products 33
Francisella Tularensis Infections Therapeutics - Dormant Products 34
Francisella Tularensis Infections – Product Development Milestones 35
Featured News & Press Releases 35
Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271 35
Sep 13, 2011: Aduro BioTech Receives Three SBIR Grants To Develop Therapeutic Vaccines 35
Aug 30, 2010: Achaogen Receives $64 Million Contract From BARDA For Development Of ACHN-490 36
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 36
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Francisella Tularensis Infections, H2 2012 7
Products under Development for Francisella Tularensis Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 10
Products under Development by Companies, H2 2012 11
AlphaRx, Inc., H2 2012 12
Aduro BioTech, H2 2012 13
Affinium Pharmaceuticals, Inc., H2 2012 14
Achaogen Inc., H2 2012 15
Evolva SA, H2 2012 16
EpiVax, Inc., H2 2012 17
Tetraphase Pharmaceuticals Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Francisella Tularensis Infections Therapeutics – Drug Profile Updates 32
Francisella Tularensis Infections Therapeutics – Discontinued Products 33
Francisella Tularensis Infections Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Francisella Tularensis Infections, H2 2012 7
Products under Development for Francisella Tularensis Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Pre-Clinical Stage Products, H2 2012 10
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos